Drug General Information |
Drug ID |
D0A4GE
|
Former ID |
DNC013486
|
Drug Name |
1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C17H17NO2
|
Canonical SMILES |
C1CNC2CC3=CC=CC=C3CC4=C2C1=CC(=C4O)O
|
InChI |
1S/C17H17NO2/c19-15-9-12-5-6-18-14-8-11-4-2-1-3-10(11)7-13(16(12)14)17(15)20/h1-4,9,14,18-20H,5-8H2
|
InChIKey |
SVRDMCXMTWERHI-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
D(2) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
Dopamine D1 receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Rap1 signaling pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Gap junction
|
Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Alcoholismhsa04020:Calcium signaling pathway
|
Amphetamine addiction
|
Morphine addiction
|
Alcoholism
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Dopamine receptor mediated signaling pathway
|
Nicotine pharmacodynamics pathwayP05912:Dopamine receptor mediated signaling pathway
|
PathWhiz Pathway
|
Dopamine Activation of Neurological Reward System
|
Reactome
|
Dopamine receptors
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
G alpha (s) signalling events
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
Genes and (Common) Pathways Underlying Drug Addiction
|
GPCR ligand binding
|
GPCR downstream signaling
|
Nicotine Activity on Dopaminergic NeuronsWP666:Hypothetical Network for Drug Addiction
|
References |
REF 1 | J Med Chem. 2007 Jan 25;50(2):171-81.Advances in development of dopaminergic aporphinoids. |